Last updated on October 2016

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris


Brief description of study

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris

Detailed Study Description

The main purpose of this study is to evaluate the efficacy, safety and long-term safety of a once daily topical application of FMX-101 Foam in subjects with moderate to severe acne. The first 12 weeks of the study involves randomized, double-blind dosing with FMX-101, 4% or matching vehicle (double-blind means neither the subject nor the study personnel knows if the subject is getting the drug or the vehicle). Subjects who successfully complete the 12-week double blind portion of the study may be offered the opportunity to continue in the trial for up to an additional 40 weeks (for a total of 1 year) and receive open-label FMX 101, 4%.

Clinical Study Identifier: TX145790

Find a site near you

Start Over

Schweiger Dermatology, PLLC

110 East 55th Street Floor 19 New York, NY USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.